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As revealed by intracellular pools of nonactive Fas (Apo-1), export of Fas to the cell surface is often impaired
in human tumors, thereby inactivating Fas ligand-mediated apoptosis. Here, we demonstrate that association
with Fas-associated phosphatase 1 (FAP-1) attenuates Fas export to the cell surface. Forced expression of
FAP-1 reduces cell surface Fas levels and increases the intracellular pool of Fas within the cytoskeleton
network. Conversely, expression of dominant-negative forms of FAP-1, or inhibition of FAP-1 expression by
short interfering RNA, efficiently up-regulates surface expression of Fas. Inhibition of Fas surface expression
by FAP-1 depends on its association with the C terminus of Fas. Mutation within amino acid 275 results in
decreased association with FAP-1 and greater export of Fas to the cell surface in melanomas, normal
fibroblasts, or Fas null cells. Identifying the role of FAP-1 in binding to, and consequently inhibition of, Fas
export to the cell surface provides novel insight into the mechanism underlying the regulation of Fas traffick-
ing, which is commonly impaired in advanced tumors with FAP-1 overexpression.
Common to advanced human tumors is a marked decrease
in, even the complete disappearance of, the expression of Fas
receptor (Apo-1; CD95) on the cell surface, where it is re-
quired to initiate the apoptosis cascade following its associa-
tion with Fas ligand (FasL). Effective Fas-mediated death sig-
naling requires the recruitment of FADD and caspase-8 to the
Fas receptor, thereby assembling the death-inducing signaling
complex (24, 31). It has been shown that in some cases the loss
of Fas surface expression can be attributed to transcriptional
silencing of the Fas promoter by cooperation between Stat3
and c-Jun (19) and that such cooperation is regulated by PI3K
signaling (22). However, it has been noted that a portion of
tumors that express Fas retain it within cytoplasmic pools
rather than on the cell surface (8, 16). Here, we demonstrate
that Fas trafficking is regulated by Fas-associated phosphatase
1 (FAP-1; synonyms, protein tyrosine phosphatase nonrecep-
tor type 13 [PTPN13] and hPTP1E/PTPL1/PTP-BAS).
FAP-1 is a 270-kDa protein containing an ezrin-like cy-
toskeleton binding domain, a leucine zipper motif, and six
PSD95/Dlg/Z-1 homology (PDZ) domains which is widely ex-
pressed in almost all tissues (7, 29, 34, 36). FAP-1 has been
implicated in the suppression of Fas-mediated apoptosis (28,
36), which requires functional interaction of either the third or
the fifth PDZ domain of FAP-1 with the extreme C-terminal
domain of Fas (35, 36, 47). However, the mechanisms by which
FAP-1 inhibits Fas-mediated death signaling are still unknown.
Colocalization of FAP-1 with Fas protein within the Golgi
apparatus has been observed in pancreatic cancer cells, imply-
ing that FAP-1 may be involved in regulating Fas processing
(45). Interestingly, increased Fas translocation from the Golgi
apparatus to the cell membrane can be induced upon cellular
treatment, as seen in hepatocytes that were exposed to bile
salts (41). An adenovirus infection that leads to forced degra-
dation of Fas by the adenovirus E3 proteins also results in
down-regulation of Fas surface expression (14, 43).
Elevated levels of FAP-1 expression have been reported in
various types of human cancer, including colon, pancreatic,
hepatocellular, hematological, and ovarian cancers (4, 13, 26,
27, 28, 30, 42, 45). Overall, the level of FAP-1 expression
positively correlates with the resistance of human tumors to
FasL-mediated apoptosis (28, 30).
As a protein tyrosine phosphatase, FAP-1 is expected to
alter tyrosine phosphorylation of its associated substrates. Al-
though such data are not yet available for human cells, the
mouse homologue of FAP-1 (PTP-BL phosphatase) dephos-
phorylates phosphoephrin B ligands following their phosphor-
ylation by Src kinases (46). In the case of Fas, information
about its own phosphorylation is very limited, although several
studies have implicated Fas phosphorylation as an important
regulatory event for its activities. For example, tyrosine ki-
nases, such as Lyn, were implicated in the generation of a Fas
receptor-linked transmembrane death signal in eosinophils
(40). A physical interaction between Fas and the tyrosine ki-
nase Fyn also has been reported (5).
Here, we demonstrate that FAP-1 association with Fas in-
hibits its export to the cell surface. The implication of our
findings for down-regulation of Fas death signaling in human
tumors is discussed.
MATERIALS AND METHODS
Cell lines. Human melanoma cell lines, TIG3 human embryonic lung fibro-
blasts, and HeLa cells were maintained in culture in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum as previously described (21).
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Mouse embryo fibroblasts prepared from Fas null mice were generated accord-
ing to standard protocols, followed by their immortalization according to the
protocol of Aaronson and Todaro (1).
Plasmid constructs. The original human Apo-1/Fas cDNA was recloned into
a pEF-GFP plasmid. Mutations within this basal sequence were generated using
the Quick Change kit (Stratagene, La Jolla, Calif.). In all cases, the integrity of
modified or cloned constructs was confirmed via sequencing. The FAP-1 expres-
sion vector and its dominant-negative variants, FAP-1CD (without the catalytic
domain) and FAP-1PDZ3 (without the PDZ3 domain, which binds Fas), have
been previously described (17, 28). Fas was mutated on Y275 to histidine or
aspartic acid and on Y75 to histidine, using a Quick Change site-directed mu-
tagenesis kit. All constructs were sequenced to assure the integrity of mutations.
Transfection, -galactosidase assay, and FACS analysis. Transient transfec-
tion of the Fas-green fluorescent protein (GFP) construct (0.2 g) together with
different expression vectors (0.7 g) and pCMV-gal (0.1 g) into 3  105 cells
was performed using Lipofectamine (Invitrogen, Carlsbad, Calif.). Eight to 30 h
after transfection, surface Fas expression in GFP-positive cells was determined
by staining them with phycoerythrin (PE)–anti-Fas monoclonal antibodies
(MAbs) and by flow cytometry. Two parameters, the percentage and number of
Fas GFP cells and the mean fluorescence intensity (MFI) of surface Fas
levels, were used to evaluate surface Fas-GFP translocation. The specific activity
of -galactosidase was used for normalization of the efficiency of transfection in
fluorescence-activated cell sorter (FACS) data.
Confocal immunofluorescence. Fas-GFP-transfected cells grown on coverslips
were fixed in 2% para-formaldehyde in phosphate-buffered saline (PBS). The
cells were then washed three times in PBS followed by permeabilization in 0.1%
Triton X-100 in PBS for 10 min with three additional 5-min washes in PBS. The
cells were incubated with primary antibodies (Abs) for 1 h at room temperature.
After additional washes, the cells were incubated with the secondary Abs labeled
with Texas Red. The cells were washed several times, and the coverslips were
mounted on glass slides in Vectashield (Vector Laboratory).
Treatment and apoptosis studies. Surface expression of endogenous Fas was
determined using anti-Fas-PE Abs (Pharmingen). Cells were permeabilized us-
ing a Cytofix/cytoperm kit (Pharmingen) for detection of internal Fas levels via
FACS. The cells were exposed to FasL as previously described (19, 20). FasL (25
to 50 ng/ml) was used in combination with cycloheximide (10 g/ml). For apo-
ptosis studies, cells were stained with propidium iodide (50 g/ml) and analyzed
by flow cytometry using a FACS Calibur flow cytometer (Becton Dickinson) with
the CellQuest program. Apoptosis was assessed by quantifying the percentage of
hypodiploid nuclei undergoing DNA fragmentation (32).
Western blot analysis and immunoprecipitation. RIPA buffer (PBS, 1% NP-
40, 0.5% sodium deoxycholate, 0.1% SDS, and protease inhibitor cocktail) was
used for the preparation of total cell extracts. Alternatively, Triton X-100-soluble
and -insoluble fractions were prepared. To this end, proteins that were soluble in
1% Triton X-100 were separated from the insoluble fraction, which was then
solubilized with 1% SDS in the presence of DNase (5 g/l) for 30 min at 37°C.
The cell lysates (50 to 100 g of protein) were resolved by SDS– 8 or 10%
polyacrylamide gel electrophoresis and processed according to the standard
protocols. The primary Abs used were rabbit anti-FAP-1 or monoclonal anti-Fas
(Pharmingen), anti--actin (Sigma), and anti-c-Src (UBI) (1:1,000 to 1:5,000).
The secondary Abs (anti-rabbit or anti-mouse) were conjugated to horseradish
peroxidase (dilution, 1:5,000). Signals were detected using the ECL system (Am-
ersham). Immunoprecipitation was carried out by standard methods (20).
RT-PCR analysis. Reverse transcription (RT)-PCR was carried out on cDNA
prepared from the RNA using primers designed to amplify 499 bp of Fas
promoter and 250 bp of the GAPDH (glyceraldehyde-3-phosphate dehydroge-
nase) cDNAs. Amplifications were carried out for 17 cycles in the presence of
[-32P]dCTP (1 min each at 94, 55, and 72°C), followed by separation on poly-
acrylamide gels and autoradiography.
FAP-1 suppression by RNAi. The p SUPER retro (pRS) RNA interference
(RNAi) system was used for the production of small RNAi transcripts to sup-
press FAP-1 gene expression as previously described (10, 11); 19-mer FAP-1-
based oligonucleotides in both sense and antisense orientations (FAP-1 RNAi,
653 GCCAGGCTATTCGAGATCG 671; control RNAi [of a different region
from FAP-1], 1190 GTTCTTTGGACCGAATCCG 1208; based on FAP-1
mRNA [GenBank accession no. NM_080683]) were synthesized and cloned into
pRS. A FAP-1 BLAST search confirmed the specificity of the selected oligonu-
cleotides, and sequencing of cloned constructs confirmed their integrity. TIG3
cells (3  105) were cotransfected with 1 g of pRS-FAP-1 RNAi and 0.2 g of
Fas-GFP or GFP, using Lipofectamine. Analysis of FAP-1 and Fas expression
was carried out 48 h later as detailed in Results.
RESULTS
Intracellular pools of Fas coincide with expression of FAP-1.
To elucidate the possible mechanism underlying impaired Fas
export, we studied melanoma cell lines exhibiting marked de-
creases in cell surface expression levels of Fas despite its in-
tracellular expression. Comparison of the overall versus cell
surface contents of Fas by FACS analysis identified the mela-
noma cell line OM431 as one that exhibits stronger intracellu-
lar expression than surface expression, whereas the melanoma
cell line FEMX revealed poor expression both internally and
externally. In contrast, most of the Fas expressed in the WM9
melanoma cells was found on the cell surface (Fig. 1A).
Immunohistochemistry with anti-Fas– fluorescein isothio-
cyanate Ab and DAPI (4,6-diamidino-2-phenylindole) nu-
clear staining further demonstrated that endogenous Fas is
mostly within intracellular pools in OM431 melanoma cells as
opposed to WM9 cells, in which it is primarily on the cell
surface (Fig. 1B). The overall levels of Fas expression recorded
via FACS analysis were also reflected in Western blot analysis
(WM9  OM431  HHMSX  FEMX cells with regard to
Fas expression [Fig. 1D]). It should be noted that Fas protein
is highly glycosylated in melanomas, and the major band has an
apparent mass of 54 kDa.
Earlier reports pointed to the correlation between FAP-1
overexpression and decreased Fas-dependent death signaling
(28, 30). Monitoring FAP-1 expression by RT-PCR (Fig. 1C)
and Western blotting (Fig. 1D) revealed low levels of FAP-1
expression in WM9 cells (in which most Fas was found on the
cell surface) and high levels of FAP-1 expression in OM431
and HHMSX cells (which exhibit internal and low cell surface
Fas expression). FEMX cells (in which total Fas expression is
low) were found to exhibit very low levels of FAP-1 expression.
These observations point to an inverse correlation between
surface Fas and FAP-1 expression.
A series of immunoprecipitation assays revealed an associ-
ation of FAP-1 with Fas that coincides with the overall level of
FAP-1 expressed (Fig. 1D) and confirms the findings of earlier
studies (47). Only a small portion of the total FAP-1 expressed
appears to be associated with Fas (Fig. 1D), suggesting that
even low levels of FAP-1 expression may suffice to affect Fas.
Subcellular fractionations were carried out to localize endog-
enous Fas and FAP-1 in melanoma cell lines. Whereas Fas
protein was found in both 1% Triton X-100-soluble and -in-
soluble fractions of FEMX cells, a substantially higher level of
Fas was found in the insoluble fraction of OM431 cells (Fig.
1E). FAP-1 was predominantly found in the insoluble fraction
of OM431 cells but not in that of FEMX cells (Fig. 1E), where
it was poorly expressed (Fig. 1D and E). These data confirm
that FAP-1 colocalizes with Fas in OM431 cells.
Fas-GFP is accumulated within cytoplasmic pools and the
Golgi apparatus in cells exhibiting impaired cell surface ex-
pression. To follow up possible effects of FAP-1 on Fas cell
surface expression, we constructed a Fas-GFP expression vec-
tor that was first tested for cellular localization and for its
ability to induce apoptosis following the addition of FasL.
Transfection of Fas-GFP to FEMX melanoma cells that ex-
press overall low levels of Fas resulted in an approximately
sixfold increase in the expression of Fas on the cell surface,
detected by an increase in the MFI of surface Fas (Fig. 2A).
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Time lapse fluorescence analysis revealed mixed cytoplasmic
and cell surface expression within 6 to 16 h, followed by pri-
mary cell surface expression after 28 h (Fig. 2B). These data
demonstrate that Fas-GFP is subject to time-dependent traf-
ficking. Total levels of Fas-GFP expression were monitored by
Western analysis of the transfected cells with anti-GFP Ab
(Fig. 2C). Two forms of Fas-GFP are likely to represent post-
translationally modified forms of Fas. These findings demon-
strate that Fas-GFP is properly expressed and localized within
the cell, similar to the endogenous form of Fas.
The addition of FasL (50 ng/ml) and cycloheximide (10
g/ml) to Fas-GFP-expressing cells resulted in a marked de-
gree of apoptosis (17 to 59%), indicating that Fas-GFP can
induce apoptosis following its activation by FasL (Fig. 2D).
These data demonstrate that Fas-GFP is functional in its traf-
ficking and ability to elicit FasL-mediated apoptosis.
We next monitored changes in the localization of Fas-GFP
in FEMX and OM431 cells that exhibited a different subcel-
lular distribution of Fas. Expression of Fas-GFP in the FEMX
cells (which exhibit overall low endogenous Fas levels) re-
vealed a partial colocalization of Fas-GFP with 	-adaptin, in-
dicating localization within the Golgi compartment. Localiza-
tion of Fas-GFP within the Golgi compartment decreased in a
time-dependent manner, as greater amounts of Fas-GFP could
FIG. 1. Fas and FAP-1 expression in human melanoma cell lines. (A) Surface and total (after cell permeabilization) Fas levels were determined
by staining with PE-conjugated anti-human Fas MAbs and flow cytometry of melanoma cells. (B) Immunostaining of endogenous Fas in WM9 and
OM431 melanoma cells. Anti-Fas MAb and fluorescein isothiocyanate-labeled secondary Abs were used. DAPI was used for nuclear staining. The
merged images were obtained by confocal microscopy. (C) RT-PCR analysis of FAP-1 mRNA levels in human melanomas. GAPDH mRNA levels
were used as an internal control. (D) Western blot analysis (W) of FAP-1 and Fas levels in melanomas. The positions of FAP-1 and of a nonspecific
form (ns) recognized by these Abs are indicated by arrowheads. The -actin level was used as a loading control. Fas and FAP-1 proteins prepared
from the indicated melanoma cell lines using RIPA buffer were subjected to coimmunoprecipitation (IP) with Abs to FAP-1 followed by
immunoblot analysis with Abs to Fas and FAP-1. Apparent molecular masses (kilodaltons) are in parentheses. (E) Western blot analyses of 1%
Triton X-100-soluble and -insoluble fractions from FEMX and OM431 cells were performed using Abs against Fas, FAP1, vinculin, RIP-1, and
Src.
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be found on the cell surface at later time points (Fig. 3A). In
contrast, OM431 cells, which mostly exhibit internal Fas ex-
pression, retained most of the Fas-GFP within the cytoplasm.
Only a small portion of Fas-GFP was found within the Golgi-
compartment (Fig. 3B). Additional staining of OM431 cells
using Abs to different subcellular compartments revealed lo-
calization of Fas within the cellular cytoskeleton based on its
colocalization with the tubulin network but not the plasma
membrane, monitored here by the use of Abs to ezrin (Fig.
3B). These data further establish changes in Fas localization
among melanoma cells, as represented with the OM431 and
FEMX cells.
FAP-1 inhibits surface expression of Fas. To assess the
possible effect of FAP-1 on Fas trafficking, we monitored
changes in Fas surface expression upon the expression of
FAP-1 in FEMX cells. Analysis of FAP-1 subcellular localiza-
tion revealed that it is predominantly localized in the insoluble
fraction of the cell (Fig. 4A), which consists of membrane and
cytoskeletal proteins. It is important to note that the total
levels of Fas-GFP (these cells have very low levels of endoge-
nous Fas) do not change after FAP-1 transfection (Fig. 4B),
suggesting that FAP-1 does not affect Fas stability. Whereas
expression of Fas-GFP in FEMX cells resulted in efficient cell
surface expression (Fig. 2 and 4C), in the presence of FAP-1
there was a marked (fivefold) decrease in Fas-GFP surface
expression (Fig. 4C). Expression of FAP-1 in FEMX cells also
caused a marked decrease in the number of Fas-GFP mole-
cules that reached the cell surface (as reflected in a decrease in
MFI from 490 to 90). The shift in the localization of Fas from
the cell surface to subcellular pools upon FAP-1 expression
FIG. 2. Fas-GFP is a functional chimeric protein that exhibits time-dependent localization on the cell surface and triggers FasL-mediated
apoptosis. (A) FEMX cells were transiently transfected with a pEF-FAS– GFP expression construct or with a pEF-GFP control plasmid. Surface
Fas levels were determined by staining the cells with anti-N-terminal Fas-PE MAbs and by FACS analysis. The MFIs of Fas and the percentages
of double-positive Fas GFP cells are indicated. (B) Intracellular localization of Fas-GFP fused protein 6 to 28 h after transfection; GFP
expression vector was used as a control. Phase reflects phase-contrast microscopy. (C) Expression pattern of total Fas-GFP was determined by
Western blot analysis 16 to 28 h after transfection; nt, nontransfected cells. The Fas-GFP fused protein has an apparent mass of 75 kDa; an
additional band, probably reflecting a posttranslationally modified form of Fas, was designated Fas-GFP*. The -actin level was used as a loading
control. (D) Apoptosis analysis of Fas-GFP-transfected FEMX cells. Apoptosis was induced by FasL (10 ng/ml)-CHX (10 g/ml) treatment.
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was also seen by confocal microscopy (Fig. 4D). To confirm
that this observation is not cell type specific, we performed a
similar analysis in HeLa cells that exhibited low levels of en-
dogenous surface Fas expression. Similar to what was seen in
the FEMX cells, forced expression of FAP-1 efficiently de-
creased the percentage of cells exhibiting surface Fas-GFP
expression in HeLa cells (data not shown). It is important to
note that despite the different protocols used for analysis of
cells via FACS and immunohistochemistry (especially concern-
ing the detachment of cells, which may affect cytoskeletal or-
ganization and protein trafficking), our confocal data are in
agreement with the FACS analysis (Fig. 4C and D) and are
supported by the notion that changes directed at cytoskeletal
proteins by selective drugs (i.e., taxol) affect trafficking of Fas,
albeit at a later time (8 to 12 h as opposed to the 30 min used
in our protocols; data not shown). The observation that FAP-1
increases the fraction of Fas-GFP (molecules and cell num-
bers) that is localized within the cytoplasm suggests that FAP-1
inhibits the export of Fas to the cell surface.
To confirm the role of FAP-1 in the regulation of Fas traf-
ficking, we tested the effects of mutant forms of FAP-1 ex-
pected to function as dominant negatives. To this end, we
chose to use FAP-1 that is unable to associate with Fas (FAP-
1PDZ3) or that is mutated within the domain expected to
enable its phosphatase activity (FAP-1CD). Since PDZ do-
main-containing proteins are known for their notorious homo-
and heterodimerization capabilities (38), it is likely that the
deleted forms of FAP-1 used in the present study efficiently
heterodimerize with the endogenous wild-type (wt) FAP-1,
which is expected to inhibit endogenous FAP-1 activities. Ac-
cordingly, we consider the forms of FAP-1 with deletions as
dominant negatives. Expression of either form of mutant
FAP-1 together with Fas-GFP in OM431 cells (Fig. 5A), which
exhibit impaired Fas cell surface expression, resulted in a sub-
stantial increase in Fas surface expression (a three- to fourfold
increase in the percentage of surface Fas-GFP-positive cells
[Fig. 5B]). Similarly, expression of Fas-GFP in the presence of
the FAP-1 dominant-negative form that lacks phosphatase ac-
tivity resulted in a two- to threefold increase in the percentage
of surface Fas-expressing cells in OM431 cells (Fig. 5B), as in
HeLa cells (data not shown) and normal human TIG3 fibro-
blasts (Fig. 6C). Overexpression of wt FAP-1 did not affect
Fas-GFP localization in OM431 cells (which already express
high levels of endogenous FAP-1). Immunohistochemistry
confirmed a decrease in the number of cells that contain in-
tracellular pools of Fas-GFP upon exogenous expression of
dominant-negative FAP-1 constructs (data not shown). In all
cases, dominant-negative forms of FAP-1 affected the relative
number of cells expressing Fas on their surfaces but not the
number of Fas molecules expressed per cell (which is reflected
in unchanged MFI values [Fig. 5B]). This is possibly due to the
limited transfection efficiency of high-molecular-weight FAP-1
FIG. 3. Time-dependent localization of Fas-GFP in melanoma cell lines. (A) Confocal analysis of Fas-GFP subcellular location in FEMX.
Localization of Fas-GFP (green) and a Golgi marker, 	-adaptin (red; the secondary Ab labeled with Texas Red), was performed at the indicated
time points. Yellow represents the overlay of green and red. (B) Confocal analysis of Fas-GFP (green) and 	-adaptin, -tubulin, and ezrin (red)
in OM431 cells.
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in these cultures. Equally plausible is the notion that additional
factors play important roles in regulating Fas trafficking to the
cell surface.
Important confirmation of these observations that followed
changes in localization of exogenously expressed Fas comes
from the analysis of the effects of FAP-1 on endogenous Fas.
Analysis of the effects of FAP-1 on the endogenous localiza-
tion of Fas was performed with the aid of GFP, used as a
marker to identify FAP-transfected cells. Expression of wt
FAP-1 caused a decrease in surface Fas expression, whereas
the expression of mutant FAP-1 increased surface Fas expres-
sion, determined as a percentage of Fas-positive and GFP-
positive cells relative to the total population of GFP-positive
cells (Fig. 5C). These findings validate the changes seen with
Fas-GFP and establish that attenuating endogenous FAP-1 is
sufficient to rescue Fas surface expression.
Analysis of normal human fibroblasts that express low levels
of Fas (Fig. 6A) was performed after forced expression of
FAP-1 (Fig. 6B). Similar to what was observed in the OM431
melanoma cells, expression of FAP decreased the levels of Fas
on the cell surface whereas dominant-negative forms of FAP-1
increased it (Fig. 6C). These observations suggest that FAP
regulation of Fas surface expression is not limited to mela-
noma cells, as it is also seen in nontransformed fibroblasts.
Given the higher efficiency of transfection in these cells com-
pared with the melanoma cultures, we have generated and
FIG. 4. FAP-1 expression attenuates Fas-GFP cell surface expression. (A) Western blot analysis of FAP-1 levels in 1% Triton X-100-soluble
and -insoluble fractions in control (empty vector) or FAP-1-tranfected FEMX cells. ns, a nonspecific form recognized by the Abs. (B) Western blot
analysis (W) of FAP-1 levels (RIPA buffer) in control (empty vector) or FAP-1-transfected FEMX cells. Both cell lines were cotransfected with
Fas-GFP. IP, immunoprecipitation. (C) Surface Fas levels were determined in transfected FEMX cells by staining them with anti-N-terminal
Fas-PE MAb and by FACS analysis. The MFIs of Fas and the percentages of double-positive Fas GFP cells are indicated. (D) Confocal images
of FEMX cells transfected with Fas-GFP plus empty vector or Fas-GFP plus FAP-1 expression construct. 	-Adaptin was used as a Golgi marker.
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expressed RNAi constructs designed to inhibit the expression
of endogenous FAP-1 (FAP-1 RNAi) and control sequences
designed from a different region of the FAP-1 sequence which
poorly affect FAP-1 expression (control RNAi). Forced ex-
pression of FAP-1 RNAi resulted in the inhibition of FAP-1
transcription, as determined by RT-PCR (not shown), and
expression, as revealed in immunoblot analysis (Fig. 6D), and
increased the level of endogenous Fas surface expression, as
determined by immunohistochemistry (Fig. 6E) and FACS
analysis (Fig. 6F). These results provide important support for
the role of FAP-1 in the inhibition of Fas surface expression.
Overexpression of FAP-1 decreases Fas surface expression
in melanoma cells that exhibit proper Fas trafficking. We next
assessed whether the expression of dominant-negative FAP-1
would enable further-increased cell surface expression of Fas
in cells in which most of the Fas is already found on the cell
surface. To this end, we used LU1205 melanoma cells, in which
the amount of endogenous surface Fas is almost equal to that
of total Fas (data not shown). Coexpression of mutant FAP-1
and Fas-GFP in LU1205 cells caused further increase (
3-
fold) in the fraction of cells exhibiting surface Fas-GFP expres-
sion, with a noticeable increase also seen in the intensity of cell
surface Fas, reflected in increased MFI (Fig. 7A). Such in-
creases coincided with smaller amounts of Fas-GFP able to
colocalize within the Golgi and cytosol fractions (Fig. 7B). In
contrast, coexpression of wt FAP-1 and Fas-GFP did not affect
surface Fas expression compared with control LU1205 cells
(due to high basal levels of FAP-1 in LU1205 cells). Consistent
FIG. 5. Mutated forms of FAP-1 increase cell surface expression of Fas. (A) Expression levels of mutated forms of transfected FAP-1 in OM431
cells were determined by Western blot analysis (W). IP, immunoprecipitation. Apparent molecular masses (kilodaltons) are in parentheses.
(B) FACS analysis of Fas-GFP surface expression was performed in OM431 cells after cotransfection with vector, FAP-1, or mutated forms of
FAP-1 using anti-N-terminal Fas-PE MAbs and C-terminally tagged GFP. The MFIs and the percentages of double-positive cells (or numbers of
double-positive cells of a total of 40,000 cells analyzed) are indicated in the upper right quadrants. (C) Effect of FAP-1 or FAP-1PGZ3 on
endogenous Fas expression in OM431 cells. The indicated constructs were cotransfected together with GFP, and 24 h later, FACS analysis allowed
the analysis of endogenous Fas levels in GFP-positive cells. The ratios of Fas GFP cells to the total number of GFP cells are indicated.
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with these observations, it was also observed that LU1205 cells
stably expressing FAP-1PDZ3 (Fig. 7C) exhibited a notice-
able increase in the level of endogenously expressed Fas on the
cell surface compared to the control LU1205-neo cells (Fig.
7D). Up-regulation of surface Fas levels upon expression of
the dominant-negative form of FAP-1 was also reflected in the
proportion of LU1205 cells that underwent apoptosis in re-
sponse to FasL and CHX stimuli (Fig. 7E). The ability of
FAP-1 to further increase Fas surface expression even in the
LU1205 cells suggests that it serves to limit the level of Fas
surface expression even in cells where a noticeable fraction of
Fas appears to be localized on the cell surface.
FAP-1 association with Fas is required for inhibition of Fas
trafficking. To further understand the mechanism underlying
the inhibition of Fas trafficking on FAP-1, we further tested
FAP-1 association with Fas in the context of its export to the
cell surface. To best mimic physiological conditions, we chose
to assess the association of wt Fas-GFP versus that of a natu-
rally occurring mutant (Y275H) reported in multiple myeloma
(25). For controls, we generated two additional mutant forms
of Fas: Y275D (the control for charge-based altered confor-
mation) and Y75H (chosen as an unrelated site). Forced ex-
pression of Fas-GFP on OM431 cells followed by immuno-
precipitation of FAP-1 revealed lower levels of C-terminal
FIG. 6. Mutated forms of FAP-1 and RNAi of FAP-1 increase cell surface expression of Fas. (A) FACS analysis of surface and total Fas levels
in TIG3 cells. (B) Western blot analysis (W) of FAS-GFP and FAP-1 levels in TIG3 cells. IP, immunoprecipitation; ns, a nonspecific form
recognized by the Abs. (C) FACS analysis of Fas-GFP surface expression was performed in TIG3 cells after cotransfection with vector, FAP-1,
or dominant-negative forms of FAP-1 using anti-N-terminal Fas-PE MAbs and C-terminally tagged GFP. (D) Western blot analysis of FAP-1 levels
in TIG3 cells transfected with pRS, FAP-1 RNAi, or control RNAi 60 h after transfection. (E) Immunohistochemistry using confocal microscopy
follows changes in surface expression of endogenous Fas in TIG3 cells that were transfected with FAP-1 RNAi or control RNAi. (F) Changes in
endogenous levels of surface Fas were determined in TIG3 cells after cotransfection of red fluorescent protein (RFP) expression vector together
with either pSR or FAP-1 RNAi and control RNAi. FACS analysis was performed for the determination of the percentage of Fas-positive cells
and Fas MFI in the population of GFP-positive cells. The error bars indicate standard deviations.
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mutants (Y275H or Y275D) in complex with FAP-1, whereas
mutation within the N-terminal site (Y75H) did not affect FAS
association (Fig. 8A). These findings suggest that FAP-1 asso-
ciation with Fas requires an intact C-terminal domain.
We next tested if mutant forms of Fas would exhibit altered
trafficking to the cell surface. Each of the GFP-Fas forms was
transfected into OM431 melanoma cells, in which Fas is pri-
marily found in the cytoplasm. Whereas Fas-GFP that was
mutated on the N-terminal site did not exhibit increased cell
surface expression, mutation within the C-terminal site in-
creased Fas trafficking to the cell surface (Fig. 8B). These re-
sults suggest that in the absence of FAP-1 association, as
shown for the C-terminal mutant, Fas trafficking is accelerated,
further supporting the negative regulation of Fas trafficking by
FAP-1.
To exclude the possible effects of endogenous Fas on Fas-
GFP trafficking, we have generated mouse embryo fibroblasts,
which were subsequently immortalized, from mice lacking the
Fas gene (2) (Fig. 9A and B). The control for actual expression
of wt and mutant Fas-GFPs that were transfected into Fas null
cells is depicted in Fig. 9C. It is important to note that the
mouse analogue of FAP-1 (PTB-BL) can interact with human
Fas (46). Monitoring the pattern of Fas-GFP surface expres-
sion in the Fas null cells revealed a low basal level of wt
Fas-GFP and the N-terminal Y75H mutant. In contrast, Fas
mutated on Y275H exhibited a marked (3-fold) increase in
the level of surface expression (MFI) (Fig. 9D), similar to its
elevated trafficking in other cell lines. Similar changes were
also observed in the normal human fibroblasts. Expression of
the C-terminal mutant R275H resulted in an increased number
of Fas molecules on the cell surface, whereas expression of
Y75H did not cause such an increase (Fig. 9E).
FIG. 7. Dominant-negative forms of FAP-1 further increase cell surface expression of Fas in LU1205 melanoma cells. (A) FACS analysis of
Fas-GFP expression in cells expressing wt and mutant forms of FAP-1 was performed as indicated in Materials and Methods. (B) Corresponding
confocal images of merged GFP-Fas and Golgi marker (	-adaptin) are shown for the experiment depicted in panel A. (C) Western blotting of
FAP-1 levels in LU1205 cells that stably express control or FAP-1PDZ3 constructs. ns, a nonspecific form recognized by the Abs. (D) FACS
analysis of Fas levels in LU1205 cells that stably express pcDNA3 (neo) or FAP-1PDZ3. (E) Apoptosis analysis of control or FAP-1PDZ3-
transfected LU1205 cells after treatment with FasL (50 ng/ml) plus CHX (10 g/ml). The percentages of apoptotic cells are indicated.
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These findings establish that inhibition of Fas trafficking to
the cell surface by FAP-1 depends on its association with FAS
via an intact C-terminal domain.
DISCUSSION
Changes in the level of Fas cell surface expression have been
widely reported and implicated in the reduction of the cell’s
ability to undergo Fas-mediated apoptosis after FasL stimula-
tion. Such changes were noted, in particular, during tumor
progression, as advanced tumors were often seen to exhibit
decreased Fas surface expression as one means of escaping
immune surveillance (3, 15, 33, 39, 42, 44). Earlier studies
highlighted the role of Stat3 and c-Jun in the negative regula-
tion of Fas transcription that resulted in attenuation of overall
Fas expression internally and on the cell surface (19). While
the earlier findings relate to a fraction of tumors tested, other
tumors were found to exhibit expression of Fas locked within
intracellular pools. The present study highlights the mecha-
nism underlying the impaired export of Fas to the cell surface,
as we demonstrate that the trafficking of Fas to the cell surface
depends on FAP-1. FAP-1 has been identified as a Fas-asso-
ciated tyrosine phosphatase and has been implicated in atten-
uating Fas death signaling (28). Our data identify the mecha-
nism underlying such inhibition, as FAP-1 expression retains
Fas in cytoplasmic pools within the cytoskeleton network,
thereby blocking its trafficking from the Golgi compartment to
the cell surface. FAP-1 structure resembles those of proteins
that are localized within the cytoskeleton network (7, 34) and
is in line with our data identifying FAP-1 within the insoluble
protein fraction of the cell. Additional analysis is required to
better pinpoint the mechanism for FAP-1 inhibition of Fas
surface expression. Among the possibilities to consider are
FAP-1 as an inhibitor of Fas export or that FAP-1 increases the
trafficking of Fas from the cell surface to intracellular pools
and thereby inhibits Fas recycling. Our results support either
model, as the excess Fas in cells that lack its cell surface
expression is primarily found within the cytoplasmic pools as-
sociated with the cytoskeleton.
We observed that, of the total amount of FAP-1 expressed,
only a small portion appears to be associated with Fas, thus
providing further support for controlled Fas–FAP-1 associa-
tion. While this implies the role of Fas modification as a pre-
requisite for association, it also suggests that FAP-1 may be
involved in the regulation of trafficking of other proteins and
that even a low expression of FAP-1 may be sufficient for
eliciting its trafficking control. Candidates include the neuro-
trophin receptor p75NTR, a member of the tumor necrosis
factor receptor superfamily shown to interact with FAP-1 (17).
It is likely that FAP-1 activities could be regulated by post-
FIG. 8. Mutation within C-terminal Fas abolishes FAP-1 association and inhibition of Fas trafficking. (A) Effect of N- and/or C-terminal
mutations of Fas on association of Fas-GFP with FAP-1. The corresponding constructs were expressed in OM431 cells following their coimmu-
noprecipitation (IP) and Western analysis (W) with the indicated Abs. The positions of Fas-GFP and the imunoglobulin heavy chain (H, Ig) are
indicated. (B) Immunohistochemical analysis of Fas-GFP expression in OM431 cells that were transfected with the wt or mutant forms of Fas-GFP.
3632 IVANOV ET AL. MOL. CELL. BIOL.
translational modification, which would render only a portion
available for both association with and effect on Fas or other
associated proteins.
The level of FAP-1 expression inversely correlates with cell
surface Fas expression. However, at least one of the cell lines
studied here, LU1205, exhibited marked cell surface expres-
sion and also expression of high levels of FAP-1. This suggests
either that expression per se may not suffice to enable FAP-1
to attenuate Fas surface expression or that FAP-1 or Fas may
be subject to changes at the genomic or posttranslational level,
explaining the limited effect in the LU1205 cells.
The nature of FAP-1 as a protein phosphatase is intriguing,
given that Fas phosphorylation remains elusive. Human Fas
(Apo-1) contains three tyrosine residues, Y75, Y216, and
Y275, the last two being positioned within the death domain.
Using NetPhos software for sequence- and structure-based
prediction of tyrosine phosphorylation sites (9), Y75 and Y275
were highlighted as the putative Tyr-phosphoryated sites. Al-
though our data suggest that the binding of Fas to FAP-1 and
to Fas requires intact tyrosine at position 275, additional stud-
ies are needed to assess the role of Fas phosphorylation in the
context of its stability and trafficking.
Understanding the nature of Fas phosphorylation may also
provide an explanation for the differences in the effect of
FAP-1 on the number of cells expressing Fas versus the num-
ber of Fas surface molecules expressed per cell. Whereas over-
expression of FAP-1 decreased both parameters, the expres-
sion of FAP-1 mutants increased the number of cells that
expressed surface Fas but not the number of Fas molecules per
cell. In contrast, the expression of a Fas mutant (Y275H or
Y275D) resulted in increased intensity (number of molecules
per cells) but not increased numbers of cells expressing surface
Fas. The nature of these changes could be attributed to addi-
tional parameters that govern Fas trafficking, including altered
FIG. 9. Effects of N- and or C-terminal mutation of Fas-GFP on its trafficking in Fas knockout (KO) cells. (A) Mouse embryo fibroblasts (MEF)
from Fas null (KO) mice have been established in culture. FACS analysis was used for monitoring Fas surface levels in KO fibroblasts before and
after transfection by Fas expression vector. ns, nonstained cells. (B) Western analysis of total Fas levels in wt and Fas KO fibroblasts. (C) Analysis
of wt and mutant Fas-GFP fusion protein expression after transfection intot Fas KO fibroblasts was done by immunoprecipitation (IP) with
anti-Fas MAb followed by Western analysis (W). (D and E) FACS analysis of surface Fas-GFP expression was performed on FAS KO (D) or TIG3
(E) cells as indicated in Materials and Methods.
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phosphorylation or glycosylation, as well as changes in Fas
stability and recycling. The role of such changes in FAP-1-
dependent Fas export is being investigated.
Our data, using a naturally occurring mutant form of Fas at
the 275 site (25), provide direct evidence for FAP-1– Fas as-
sociation as a prerequisite for Fas trafficking inhibition. Our
data are in agreement with the observation that the C-terminal
peptide that harbors the last three amino acids of the Fas
protein increases Fas surface expression (37, 45), probably due
to interference with FAP-1 binding. It is interesting that the
extreme C-terminal domain (i.e., the last three amino acids of
the Fas protein) is not conserved in evolution (i.e., mouse Fas
lacks these residues), further highlighting the requirement for
the integrity of Fas conformation within the carboxyl end of
the protein, as revealed in our analysis of the Fas mutants at
amino acid 275.
Elevated FAP-1 expression in human tumors is often seen
and has been linked with impaired Fas-mediated apoptosis (26,
28, 30, 44, 45). Our findings, which provide direct evidence for
the effect of FAP-1 on Fas cell surface expression, point to the
mechanism underlying the inhibition of Fas surface expression
commonly seen in advanced human tumors. NFB, which has
been implicated in melanoma progression (12, 23), was also
linked to the regulation of FAP-1 (18).
FAP-1 expression may also play a role in dictating the pri-
mary apoptosis cascade in normal untransformed cells, as
shown here in normal TIG3 lung fibroblasts. This is in accord
with the notions that pancreatic  cells are triggered to express
cell surface Fas following progressive insulitis (6) and that bile
salts mediate hepatocyte apoptosis by increasing cell surface
trafficking of Fas (41).
Taken together, our findings provide direct evidence for the
role of FAP-1 in the regulation of Fas expression on the cell
surface, thereby highlighting novel insights into the mecha-
nisms underlying the regulation of Fas cell surface expression
in normal and tumor cells. The use of melanoma cells with very
low Fas expression (FEMX) allowed analysis in a model sys-
tem (using Fas-GFP) resembling Fas null cells, albeit in a true
melanoma setting. FAP-1 inhibition of Fas surface expression
has also been observed in the context of different melanoma
cultures, as well as in untransformed human fibroblasts, further
validating our model and highlighting its physiological rele-
vance.
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